These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20222811)

  • 1. Thrombocardiology: an update.
    Arnesen H
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):331-3. PubMed ID: 20222811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts in coronary thrombolysis.
    Eisenberg PR
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1161-70. PubMed ID: 1400079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation.
    Nieuwlaat R; Olsson SB; Lip GY; Camm AJ; Breithardt G; Capucci A; Meeder JG; Prins MH; Lévy S; Crijns HJ;
    Am Heart J; 2007 Jun; 153(6):1006-12. PubMed ID: 17540203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of antithrombotic drugs in older people.
    Tufano A; Cerbone AM; Di Minno G
    Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives].
    Scardi S; Mazzone C
    Ital Heart J Suppl; 2003 Mar; 4(3):201-9. PubMed ID: 12784754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism.
    Chesebro JH; Fuster V
    Circulation; 1986 Nov; 74(5 Pt 2):III1-10. PubMed ID: 3533316
    [No Abstract]   [Full Text] [Related]  

  • 7. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes.
    Lopes RD; Starr A; Pieper CF; Al-Khatib SM; Newby LK; Mehta RH; Van de Werf F; Mahaffey KW; Armstrong PW; Harrington RA; White HD; Wallentin L; Granger CB
    Am J Med; 2010 Feb; 123(2):134-40. PubMed ID: 20103022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of antithrombotic drugs in artery disease.
    Gallus AS
    Clin Haematol; 1986 May; 15(2):509-59. PubMed ID: 3524934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral anticoagulation after myocardial infarction.
    Hurlen M; Arnesen H
    Herz; 2008 Feb; 33(1):38-43. PubMed ID: 18273576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
    Aalbers J
    Cardiovasc J Afr; 2012 Oct; 23(9):525-6. PubMed ID: 23108522
    [No Abstract]   [Full Text] [Related]  

  • 11. The number needed to harm: is it too optimistic?
    Mancini GB; Schulzer M
    Can J Cardiol; 2004 Nov; 20(13):1375; author reply 1376. PubMed ID: 15612137
    [No Abstract]   [Full Text] [Related]  

  • 12. Tailored antithrombotic therapy for acute coronary syndromes.
    Fitchett D
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):935-44. PubMed ID: 18666844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [European Society of Cardiology guidelines on ST-elevation myocardial infarction: what is new?].
    De Servi S; D'Urbano M
    G Ital Cardiol (Rome); 2009 Jul; 10(7):490-2. PubMed ID: 19761104
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anticoagulant and thrombolytic agents in acute coronary syndromes].
    Schwarz M; Saurbier B; Bode C
    Hamostaseologie; 2008 Dec; 28(5):438-47. PubMed ID: 19132173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]).
    Schwammenthal Y; Bornstein N; Schwammenthal E; Schwartz R; Goldbourt U; Tsabari R; Koton S; Grossman E; Tanne D
    Am J Cardiol; 2010 Feb; 105(3):411-6. PubMed ID: 20102959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
    Budaj A; Eikelboom JW; Mehta SR; Afzal R; Chrolavicius S; Bassand JP; Fox KA; Wallentin L; Peters RJ; Granger CB; Joyner CD; Yusuf S;
    Eur Heart J; 2009 Mar; 30(6):655-61. PubMed ID: 18713759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cardiovascular events after acute coronary syndrome.
    Wallentin L
    Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fondaparinux in patients with acute coronary syndromes.
    Bassand JP; Richard-Lordereau I; Cadroy Y
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1013-26. PubMed ID: 18035917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Main antithrombotic drugs in the therapy and prevention of arterial and venous thrombosis].
    Ferlito S
    Minerva Cardioangiol; 1996 Jun; 44(6):299-312. PubMed ID: 8927260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.